Cardinal Health (CAH) Could Be 7% Below Fair Value After Its Recent Pullback

Cardinal Health (CAH) recently outpaced the broader market with a 1.38% gain ahead of its upcoming earnings report on August 11, 2026. This has put fresh attention on the stock’s recent performance.

See our latest analysis for Cardinal Health.

Looking beyond the latest session, Cardinal Health’s share price return has been positive over the year, with shorter term momentum softening after a recent 30 day pullback, while longer term total shareholder returns remain strong.

If Cardinal Health’s move has you watching healthcare more closely, this is a good moment to see which other companies are gaining attention through our healthcare focused 40 healthcare AI stocks.

After Cardinal Health’s strong multiyear run and recent pullback, some investors may see a chance to add now, while others prefer to wait for a deeper reset. How does today’s valuation stack up against that trade off?

Most Popular Narrative: 7.2% Undervalued

Cardinal Health's most followed valuation narrative places fair value at about $250.53, compared with the latest close at $232.51. That gap is built on detailed assumptions about future revenue, margins and earnings.

The company's investments in automation, advanced supply chain technology, and new distribution centers are expected to deliver long-term operational efficiencies and cost savings, supporting improved net margins and free cash flow as healthcare shifts to value-based and outpatient models.

Read the complete narrative. Read the complete narrative.

Want to see what is behind that fair value for Cardinal Health? The narrative focuses on steady revenue expansion, firmer profit margins and a richer earnings profile over time. Curious which specific growth and profitability assumptions drive those cash flow projections and support a higher valuation anchor?

Result: Fair Value of $250.53 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Cardinal Health’s story can change quickly if tariff headwinds in Global Medical Products and Distribution or pressure on major customer contracts hit margins harder than analysts expect.

Find out about the key risks to this Cardinal Health narrative.

Another View on Cardinal Health’s Valuation

Cardinal Health looks about 7.2% undervalued on the narrative fair value of $250.53, yet its current P/E of 35x sits above the US Healthcare industry at 26.9x, the peer average at 28.1x, and the fair ratio of 29.2x. That richer multiple points to valuation risk if sentiment cools.

To see how that richer P/E could adjust over time, and what it might mean if the market moves closer to the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed sentiment around Cardinal Health, this is a good moment to review the data yourself and move quickly to decide where you stand. To weigh up both sides before you act, take a closer look at the 2 key rewards and 2 important warning signs.

Looking For More Investment Ideas Beyond Cardinal Health?

If Cardinal Health has your attention, do not stop there. Use the Simply Wall St Screener to spot other potential opportunities before they move away.

• Target stability in your core holdings by checking companies on the 83 resilient stocks with low risk scores that score well on resilience.
• Hunt for strong businesses trading below what their fundamentals suggest by reviewing the 49 high quality undervalued stocks for potential value candidates.
• Add potential income streams to your watchlist by scanning the 8 dividend fortresses that focus on higher yielding dividend payers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com